Head and neck for Viralytics

By Kate McDonald
Tuesday, 09 December, 2008

Sydney biotech Viralytics has been authorised to start a trial of its Cavatak oncolytic virus technology in head and neck cancers.

The company is running Phase I trials of the technology in late stage melanoma, prostate and breast cancers.

The new trial will involve nine patients with recurrent, inoperable tumours of the head and neck.

Cavatak is a coxsackievirus-based formulation which attaches itself to receptors on the cell surface that are highly expressed in some solid tumours.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd